In patients affected by metastatic NSCLC, clinical guidelines recommend the testing of activating mutations, the majority of which are linked with an activation of EGFR that occurs in 10–20% of Caucasian and 50% of Asian patients [1,6]. Here, EGFR is linked to non-small cell lung carcinoma.